The first half of 2025 has seen an acceleration of M&A activity, including large-scale life sciences transactions, such as Merck’s $3.9 billion acquisition of SpringWorks, Sanofi’s $9.5 billion acquisition of Blueprint Medicines, and Johnson & Johnson’s $14.6 billion acquisition of Intra-Cellular Therapies, as well as notable developments in litigation and enforcement by European and UK regulators. As discussed in this update, these outcomes can provide important guidance for life sciences companies as they structure their transactional and regulatory activity.
Read the full Antitrust Life Sciences Quarterly Update for Q2 2025 written by Antitrust lawyers Arman Oruc, Andrew Lacy, Eram Khan, Alexandra Russell, Laurenz Bové, and Nicholas Franco here.